אנטרה ביו מדווחת על תוצאות כספיות ועדכונים עסקיים לרבעון השני של 2025

ירושלים, 8 באוגוסט 2025 (GLOBE NEWSWIRE) –

אנטרה ביו Entera Bio Ltd.(נאסד"ק: ENTX), מובילה בפיתוח פפטידים וחלבונים טיפוליים הניתנים דרך הפה, מדווחת על תוצאות כספיות ועדכונים עסקיים מרכזיים לרבעון שהסתיים ב-30 ביוני 2025.

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

• FDA providespivotal agreement on EB613 Phase 3 design, confirmingBone Mineral Density (BMD) as primary endpoint and clearingstreamlined pathway for first oral anabolic osteoporosis treatment
• Significantregulatory and pipeline advancements achieved including FDA waiver ofadditional safety studies and next-gen EB613 expected to enterPhase 1 in November 2025
• Strong momentumacross OPKO collaboration with obesity program showing promisingpreclinical data; and EB612 oral PTH directed hypoparathyroidismprogram candidate validation
• Strong balancesheet provides runway through mid-Q3 2026, including dedicated OPKOcollaboration funding

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) –

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

"Last week's FDA agreement on using BMD as the primary endpoint for EB613's Phase 3 program represents a pivotal milestone in our journey to bring the first oral anabolic osteoporosis tablet treatment to market," said Miranda Toledano, Chief Executive Officer of Entera. "This unprecedented regulatory alignment validates both the strength of our clinical data and our strategic vision that began taking shape in July 2022. The concurrence opens the door to addressing a massive unmet need - with less than 25% of the world's 200 million osteoporotic women having access to safe, effective, and affordable treatment options, and no new therapies approved in this space since 2019. Beyond EB613, throughout Q2, we continued building momentum across our entire pipeline, including presenting promising pharmacokinetic data for our oral GLP-1/glucagon dual agonist program with OPKO. With our strengthened cash position of $18.9 million, including dedicated OPKO collaboration funding, we are well-positioned to execute on multiple value-creating milestones across 2025 and beyond."

Key Recent Highlights

EB613: First Oral PTH(1-34) Anabolic Treatment for Osteoporosis

• FDA Agreementthat BMD Primary Endpoint Would Support NDA: In a July Type Ameeting, FDA provided written concurrence on our Phase 3 study design - asingle multinational, randomized, double-blind, placebo-controlled,24-month study in women with postmenopausal osteoporosis, where change intotal hip BMD is evaluated as the primary endpoint, and incidence of newor worsening vertebral fractures is evaluated as the key secondaryendpoint. As a 505(b)(2) application, the submission will rely on FDA'sprevious findings of effectiveness and safety for the Reference ListedDrug Forteo^®, where the correlation between BMD and fracture hasbeen well-established. The study is designed and powered to demonstrate astatistically significant increase in total hip BMD, coupled with apositive trend on vertebral fracture reduction as key secondary endpointto provide substantial evidence of effectiveness. This FDA decision isindependent of the Agency's qualification of the SABRE BMD Initiativewhich is still expected within 2025.

• Regulatory Burden Significantly Reduced: In May andJune, Entera received written agreements from FDA that dedicated oralcarcinogenicity studies and comprehensive nonclinical developmental andreproductive toxicity (DART) studies are not warranted given the totalityof evidence generated fromForteo^® literature andnonclinical studies conducted with EB613.
• Strong Clinical Data Gains Scientific Recognition: In April,Dr. Rachel B Wagman presented early effects of EB613 on trabecular andcortical bone using 3D-DXA at the 2025 WCO-IOF-ESCEO Congress.Additionally, 3D Shaper Phase 2 data was selected for oral presentation atASBMR 2025 in September.
• Next-Generation EB613 Advancing: "AdvancingOral Anabolic Treatments for Osteoporosis: Pre-Clinical Data for Next GenEB613 Tablet Utilizing N-Tab™ Proprietary Technology" was selectedfor poster presentation at ASBMR 2025. Next Gen EB613 is being developedwith a new generation of Entera's N-TAB™ platform and is expected to enterthe clinic in a Phase 1 Safety and PK Study in November 2025.
• Strategic Regulatory Engagement: In June, CEOMiranda Toledano participated in the Boston "CEO Forums: An FDAListening Tour to Engage Pharma and Bio CEOs" and presented aone-minute brief on osteoporosis and potential regulatory reform to spurinnovation.

First PTH (1-34) Tablet Protein Replacement Therapy for Hypoparathyroidism

• First pre-clinicalPK/PD data from undisclosed collaborative research with long-acting PTHagonist as a once-daily tablet format is expected by end of year.

OPKO Health Collaboration Programs

• FirstGLP-1/Glucagon Agonist (Oxyntomodulin) Peptide Tablet Candidate for Obesity: In June, aposter at ENDO2025 reported PK data from a mini-pig study of oralOPK-88006 (dual GLP-1/glucagon receptor agonist in partnership with OPKOHealth, Nasdaq: "OPK") which showed plasma levels consistentwith those reported in humans for the highest subcutaneous dose of Wegovy™(semaglutide) weekly injection, a standard of care for the treatment ofobesity. The reported pharmacological data supports a once-daily tabletregimen of this first-in-class oral dual agonist. A Phase 1 study is beingplanned and IND filing is expected in H1 2026.
• First GLP-2Peptide Tablets for Short Bowel Syndrome: In June,Entera in partnership with OPKO's "First-in-Class Oral GLP-2 Analogfor Treatment of Short Bowel Syndrome" abstract was selected forposter presentation at the 47th European Society for Clinical Nutrition& Metabolism ("ESPEN") Congress.

Financial Results for the Quarter Ended June 30, 2025

Cash and cash equivalents were $18.9 million as of June 30, 2025, including $8.0 million in restricted cash designated to fund the OPKO collaboration through Phase 1 studies of oral GLP-1/glucagon candidate OPK-88006. Cash on hand is expected to support operations through mid-third quarter 2026.

Net loss was $2.7 million, or $0.06 per ordinary share, for the three months ended June 30, 2025, compared to $2.1 million, or $0.06 per ordinary share, for the three months ended June 30, 2024.

Research and development expenses were $1.5 million for the three months ended June 30, 2025, compared to $1.1 million for the three months ended June 30, 2024, an increase of $0.4 million. The increase was primarily due to regulatory activities and Phase 3 planning for EB613.

General and administrative expenses were $1.1 million for the three months ended June 30, 2025, compared to $1.1 million for the three months ended June 30, 2024.

Total operating expenses were $2.7 million for the three months ended June 30, 2025, compared to $2.2 million for the three months ended June 30, 2024.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab™) and a pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 with alignment from FDA on the use of BMD as its primary endpoint. The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

Contact:

Corporate Contact:

Ms. Miranda Toledano

Chief Executive Officer

Entera Bio

Email: [email protected]

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire